Angioedema is a medical condition characterized by swelling beneath the skin or mucosa. The angioedema treatment market is driven by the increasing prevalence of angioedema, which can be caused by genetic factors, allergies, infections, and medications. The rising demand for effective treatment options, such as antihistamines, corticosteroids, and bradykinin receptor antagonists, is expected to boost the growth of the market. Additionally, the increasing awareness among patients and healthcare professionals about the diagnosis and management of angioedema is also expected to fuel market growth. However, the high cost of treatment and limited availability of approved drugs for some forms of angioedema may restrain market growth. Furthermore, adverse effects associated with some of the treatment options may also hinder market growth.
Key players in Angioedema Treatment Market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.
Leading Companies in the Angioedema Treatment Industry:
1. Shire plc
Shire plc is a biopharmaceutical company headquartered in Dublin, Ireland. It was founded in 1986 and operates in over 70 countries worldwide. Shire is focused on developing treatments for rare diseases and has a portfolio of products for the treatment of hereditary angioedema (HAE), including Firazyr, Cinryze, and Takhzyro. In November 2022, Shire announced that it had submitted a Biologics License Application (BLA) to the US FDA for its HAE treatment product called SHP643.